[Pharmacological potentials for activating the fibrinolytic system].
Increasing insight into the mechanism of thrombolysis has led to the development of highly effective thrombolytic agents. Further progress in thrombolytic therapy is expected by the use of extrinsic plasminogen activator from vascular endothelium and of temporarily blocked (acylated) fibrinolytic enzymes. Extensive studies on fibrinolytic/thrombolytic substances will lead to a new generation of activator of fibrinolysis that interferes with the biosynthesis and release of plasminogen activator. Such agents will be suited for treatment of hyperfibrinolytic states.
D000818:Animals; D004211:Disseminated Intravascular Coagulation / Q000188:drug therapy; D004789:Enzyme Activation / Q000187:drug effects; D005260:Female; D005337:Fibrin / Q000378:metabolism; D005342:Fibrinolysis / Q000187:drug effects*; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010447:Peptide Hydrolases / Q000627:therapeutic use; D010958:Plasminogen / Q000378:metabolism; D010960:Plasminogen Activators / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use; D051381:Rats; D013300:Streptokinase / Q000627:therapeutic use; D013917:Thrombin / Q000627:therapeutic use; D013927:Thrombosis / Q000188:drug therapy
D005343:Fibrinolytic Agents; D005337:Fibrin; D010958:Plasminogen; D010447:Peptide Hydrolases; D013300:Streptokinase; D010960:Plasminogen Activators; D013917:Thrombin
Pharmakologische Möglichkeiten zur Aktivierung des fibrinolytischen Systems.